Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

C4 Therapeutics (CCCC) EBITDA (2019 - 2026)

C4 Therapeutics has reported EBITDA over the past 8 years, most recently at -$25.5 million for Q1 2026.

  • For Q1 2026, EBITDA rose 3.16% year-over-year to -$25.5 million; the TTM value through Mar 2026 reached -$104.2 million, down 1.33%, while the annual FY2025 figure was -$105.0 million, 0.13% changed from the prior year.
  • EBITDA for Q1 2026 was -$25.5 million at C4 Therapeutics, down from -$20.6 million in the prior quarter.
  • Over five years, EBITDA peaked at -$17.8 million in Q2 2024 and troughed at -$35.9 million in Q4 2022.
  • A 5-year average of -$29.2 million and a median of -$28.6 million in 2024 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: crashed 120.62% in 2022 and later skyrocketed 49.54% in 2024.
  • Year by year, EBITDA stood at -$35.9 million in 2022, then rose by 5.39% to -$34.0 million in 2023, then dropped by 2.94% to -$35.0 million in 2024, then skyrocketed by 41.17% to -$20.6 million in 2025, then dropped by 23.94% to -$25.5 million in 2026.
  • Business Quant data shows EBITDA for CCCC at -$25.5 million in Q1 2026, -$20.6 million in Q4 2025, and -$32.0 million in Q3 2025.